Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 283

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1
Chunk 283
---

    showed little/no metabolism by CYP enzymes.

    Telomir-1
    Reaction Phenotyping Using Liver S9
     
    Mouse,
    rat, monkey and human liver
     
    Identification
    of the Enzymes Involved in the Metabolism of Telomir-1 Using Hepatic S9 Fraction
     
    The
    compound does not appear to be a substrate of cytochrome P450 enzymes. There was little/no metabolism of Telomir-1 in dog S9, consistent
    with the fact that the dog lacks aldehyde oxidase activity.

    Cytochrome
    P450 (CYP) reaction phenotyping
     
    Human
     
    To
    evaluate the potential of Telomir-1 to be a victim of drug-drug interactions
     
    Telomir-1
    was extensively metabolized in mouse, rat, monkey, dog, and human hepatocytes.

    Cytochrome
    P450 (CYP) inhibition
     
    Human
     
    To
    evaluate the potential of Telomir-1 to cause drug-drug interactions as a perpetrator
     
    Telomir-1
    (up to 100 µM) did not inhibit any of the tested CYP enzymes.

    Plasma
    protein binding
     
    CD-1
    mouse, SD rat, Beagle dog, Cynomolgus monkey and human
     
    To
    know the unbound fraction of Telomir-1 in plasma
     
    Not
    highly protein bound

    Maximum
    Tolerated Dose and 7 Day Repeat-Dose Toxicity/Toxicokinetic Study in Rats
     
    Sprague
    Dawley Rats
     
    To
    evaluate and characterize the toxicokinetic and toxicity of Telomir-1 and to estimate the MTD of Telomir-1 following
     
    The
    MTD following 7 days of repeated administration of Telomir-1 at dose levels of 50, 200, and 750 mg/kg/day in rats was determined
    to be ≥ 750 mg/kg/day

    Maximum
    Tolerated Dose and 7 Day Repeat-Dose Toxicity/Toxicokinetic Study in Dogs
     
    Beagle
    Dogs
     
    To
    evaluate and characterize the toxicokinetic and toxicity